Explore Business Standard
The government has notified a uniform code for marketing practices for the medical device industry in order to curb unethical practices. In a notification, Department of Pharmaceuticals (DoP) has asked the medical devices association to prohibit organising workshops abroad for healthcare professionals, offering them hotel stays or monetary grants. "All associations should constitute an ethics committee for marketing practices in medical devices (ECMPMD), upload it on their websites along with a detailed procedure of complaints, which will be linked to the UCPMP portal of Department of Pharmaceuticals," the notification said. The DoP has also sought disclosures form medical devices firms for particulars related to distribution of evaluation samples and expenses incurred on conferences , workshops, seminars etc. As part of the code, a medical device must not be promoted prior to receipt of product approval by the regulatory authority, the notification said. "The word safe or safet
The Medical Device Park being set up on 265 acres in Solan district would create 10,000 direct and indirect jobs, Himachal Pradesh Industries Minister Harshwardhan Chauhan told the state assembly on Tuesday. The upcoming park in Manjholi village panchayat under Nalagarh assembly constituency would provide direct and indirect employment to 10,000 persons, Chauhan said in response to a question. The minister said that the state government will bear the entire expenditure on the project which is expected to be completed by December 31, 2025. No technical sanction was pending and there is possibility of setting up 65 industrial units under the project, he added. Meanwhile, chief minister Sukhvinder Singh Sukhu informed the state assembly that 2,708 cases of forest fires were reported during six months of the current year ending June 2024, but there was no loss of human life. In reply to another question of BJP member Sukh Ram Chowdhary, the chief minister said that out of 55 hotels ru
The government makes all efforts to ensure affordable and accessible treatment is available for cancer patients amid a rise in cases in India, Health Minister JP Nadda said on Friday. Replying to supplementary questions during Question Hour in the Lok Sabha, Nadda said the government made all efforts to ensure that affordable and accessible treatment was available to the patients. "The number of cancer cases is going up, it is increasing by almost 2.5 per cent every year," Nadda said. In men, cases of oral and lung cancer are on the up while more women are getting breast cancer, he added. More than 15.5 lakh cancer cases are being registered every year, Nadda said. "There is a list of 131 essential cancer medicines, which are in Schedule 1, (that) are monitored and (their) pricing is decided by the government. These are the commonly used medicines," Nadda said. He said patients cumulatively saved around Rs 294 crore due to this price control. "There are 28 combinations, which ar
Alembic Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Icatibant injection indicated for the treatment of acute attacks of hereditary angioedema in adults. The approval by the US Food & Drug Administration (USFDA) is for the Abbreviated New Drug Application (ANDA) for Icatibant injection of strengths 30 mg/3 mL (10 mg/mL) single-dose prefilled syringe, Alembic Pharmaceuticals said in a regulatory filing. This is the first peptide product approval from the USFDA received by the company, Alembic Pharma said. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Firazyr Injection, 30 mg/3 mL (10 mg/mL), of Takeda Pharmaceuticals USA, Inc, it added. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Hereditary angioedema is a disorder characterised by recurrent episodes of severe swelling (angioedema)
The Indian Council of Medical Research Director General Dr Rajiv Bahl on Monday criticised a recently published study on the long-term safety analysis of the Covaxin in adults and adolescents for its poor methodology and design, and clarified the article misleadingly and erroneously "acknowledges" ICMR. Dr Bahl said the study had no control arm of unvaccinated individuals for comparing the rates of events between the vaccinated and unvaccinated groups. Hence, the reported events in the study cannot be linked or attributed to COVID-19 vaccination. The ICMR is not associated with the study and has not provided any financial or technical support for the research, Dr Bahl said. The ICMR DG has written a letter to the authors of the paper and Editor of the journal to immediately remove the acknowledgement to ICMR and publish an erratum. A research paper, titled 'Long-Term Safety Analysis of the BBVl52 Coronavirus Vaccine in Adolescents and Adults: Findings from a l-Year Prospective Stud